(Q44525390)

3 December 2017

title

Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study (English)

1 reference

3 December 2017

1 reference

2

1 reference

3 December 2017

5

Ruben Burgos-Vargas

1 reference

3 December 2017

10

Joan T Merrill

1 reference

3 December 2017

Richard Furie

1

1 reference

3 December 2017

Tien-Tsai Cheng

3

1 reference

3 December 2017

Frederic Houssiau

4

1 reference

3 December 2017

Shun-Le Chen

6

1 reference

3 December 2017

Jan L Hillson

7

1 reference

3 December 2017

Stephanie Meadows-Shropshire

8

1 reference

3 December 2017

Michael Kinaszczuk

9

1 reference

3 December 2017

publication date

1 February 2014

1 reference

3 December 2017

published in

Arthritis & Rheumatology

1 reference

3 December 2017

volume

66

1 reference

3 December 2017

issue

2

1 reference

3 December 2017

page(s)

379-389

1 reference

T cells and B cells in lupus nephritis

3 December 2017

cites work

1 reference

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

21 January 2018

1 reference

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.

21 January 2018

1 reference

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions

21 January 2018

1 reference

Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials

21 January 2018

1 reference

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus

21 January 2018

1 reference

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

21 January 2018

1 reference

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study

21 January 2018

1 reference

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

21 January 2018

1 reference

Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.38260

1 reference

3 December 2017

1 reference